Hanefeld conducted a meta-analysis of 7 long term studies and reported that acarbose could prevent myocardial infarction and CV disease in type 2 diabetic patients though most of them were already on intensive concomitant CV medication.[37] Our study also revealed that DPP-4 inhibitors using had lower risk of mortality, which was consistent with Monami meta-analysis.[38] But these 2 extra findings might need more rigorous matching study of insulin and other possible confounding factors to clarify them in the real word practice. The gene discussed is DPP4; the disease is myocardial infarction.